Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes

Chemico-Biological Interactions

Volumn 142, Issue 1-2, 2002, Pages 73-82

  Hewitt, Nicola J ^a   Lloyd, Scott ^a   Hayden, Mike ^a   Butler, Ryan ^a   Sakai, Yumiko ^a   Springer, Ryan ^a   Fackett, Andrew ^a   Li, Albert P ^b  

^a In Vitro Technologies Inc   (United States)

^b Phase 1 Molecular Toxicology Inc   (United States)

Author keywords

Cytotoxicity; Drug metabolism; Hepatotoxicity; Human hepatocytes; P450; Troglitazone

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARYL SULFOTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; ISOENZYME; TROGLITAZONE;

ARTICLE; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYOPRESERVATION; DRUG CYTOTOXICITY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL; OXIDATION; XENOBIOTIC METABOLISM;

ADENOSINE TRIPHOSPHATE; ARYLSULFOTRANSFERASE; CHROMANS; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0037058255     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(02)00055-8     Document Type: Article

References (16)

1. Henry R.R. Thiazolidiniones. Curr. Ther. Diabetes. 26:1997;553-573.
2. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., Juarbe H.M. Two cases of severe clinical and histological hepatotoxicty associated with troglitazone. Ann. Int. Med. 129:1998;36-38.
3. Neuschwander-Tetri B.A., Isley W.L., Oki J.C., Ramrakhiani S., Quiason S.G., Phillips N.J., Brunt E.M. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann. Int. Med. 129:1998;38-41.
4. Shibuya A., Watanabe M., Fujita Y., Saigenji J., Kuwao S., Takahashi H., Takeuchi H. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 21:1998;2140-2143.
5. Herrine S.K., Chouhary C. Severe hepatotoxicity associated with troglitazone. Ann. Int. Med. 130:1999;163-164.
6. Loi C.M., Young M., Randinitis E., Vassos A., Koup J.R. Clinical pharmacokinetics of troglitazone. Clin. Pharm. 37:1999;91-104.
7. Kassahun K., Pearson P.G., Tang W., McIntosh I., Leung K., Elmore C., Dean D., Wang R., Doss G., Baillie T.A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14:2001;62-70.
8. Kawai K., Kawasaki-Tokui Y., Odaka T., Tsuruta F., Kazui M., Iwabuchi H., Nakamura T., Kinoshita T., Ikeda T., Yoshioka T., Komai T., Nakamura K. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzeim Forsch Drug Res. 47:1997;356-368.
9. Ott P., Ranek L., Young M. Pharmacokinetics of troglitazone, PPAR-gamma antagonist, in patients with hepatic insufficiency. Eur. J. Clin. Pharm. 54:1998;567-571.
10. Funk C., Ponelle C., Scheuermann G., Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59:2001;627-635.
11. Kostrubsky V.E., Sinclair J.F., Ramachandran V., Venkataramanan R., Wen Y.H., Kindt E., Galchev V., Rose K., Sinz M., Strom S.C. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab. Disp. 28:2000;1192-1197.
12. A.P. Li, C. Lu, J.A. Brent, C. Pham, A. Fackett, C.E. Ruegg, P.M. Silber, Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. (121) 17-35.
13. Li A.P., Gorycki P.D., Hengstler J.G., Kedderis G.L., Koebe H.G., Rahmani R., de Sousas G., Silva J.M., Skett P. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: concensus of an international expert panel. Chem. Biol. Interact. 121:1999;117-123.
14. Loretz L.J., Li A.P., Flye M.W., Wilson A.G.E. Optimization of cryopreservation procedures for rat and human hepatocytes. Xenobiotica. 19:1989;489-498.
15. Li A.P., Roque M.A., Beck D.J., Kaminski D.L. Isolation and culturing of hepatocytes from human livers. J. Tiss. Cult. Meth. 14:1992;139-146.
16. S. Lloyd, M.J. Hayden, R.K. Butler, Y. Sakai, R. Springer, A. Fackett, N.J. Hewitt, A.P. Li, Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from thirty-seven donors, in press.